EcoDrugPlus

Cholinergic Receptor Muscarinic 1

Ensembl ID : ENSLOCG00000017613
Gene Symbol: CHRM1
3 Cross references
101 Possible Orthologues:

Cholinergic Receptor Muscarinic 3

Ensembl ID : ENSLOCG00000017368
Gene Symbol: CHRM3
3 Cross references
255 Possible Orthologues:

Cholinergic Receptor Muscarinic 4

Ensembl ID : ENSLOCG00000005536
Gene Symbol: CHRM4
3 Cross references
184 Possible Orthologues:

Cholinergic Receptor Muscarinic 5

Ensembl ID : ENSLOCG00000017709
Gene Symbol: CHRM5
3 Cross references
263 Possible Orthologues:

Cholinergic Receptor Nicotinic Alpha 3 Subunit

Ensembl ID : ENSLOCG00000014294
Gene Symbol: CHRNA3
1 Cross references
202 Possible Orthologues:

Cholinergic Receptor Nicotinic Alpha 4 Subunit

Ensembl ID : ENSLOCG00000001635
Gene Symbol: CHRNA4
3 Cross references
204 Possible Orthologues:

Cholinergic Receptor, Muscarinic 2a

Ensembl ID : ENSLOCG00000017918
Gene Symbol: CHRM2A
1 Cross references
259 Possible Orthologues:

Cholinergic Receptor, Nicotinic, Alpha 7a (Neuronal)

Ensembl ID : ENSLOCG00000014571
Gene Symbol: CHRNA7A
1 Cross references
250 Possible Orthologues:

Coagulation Factor Ii Thrombin Receptor

Ensembl ID : ENSLOCG00000017527
Gene Symbol: F2R
2 Cross references
325 Possible Orthologues:

Coagulation Factor Ii Thrombin Receptor

Ensembl ID : ENSLOCG00000017528
Gene Symbol: F2R
1 Cross references
325 Possible Orthologues:

Coagulation Factor Ii Thrombin Receptor

Ensembl ID : ENSLOCG00000017526
Gene Symbol: F2R
1 Cross references
325 Possible Orthologues:

Coagulation Factor Iii, Tissue Factor

Ensembl ID : ENSLOCG00000008142
Gene Symbol: F3
3 Cross references
243 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).